FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947155305> ?p ?o ?g. }

• W2947155305 abstract "Summary In the outpatient setting, glucagon‐like peptide‐1 (GLP‐1) receptor agonists have proved to be highly efficacious drugs that provide glycaemic control with a low risk of hypoglycaemia. These characteristics make GLP‐1 receptor agonists attractive agents to treat dysglycaemia in perioperative or high‐dependency hospital settings, where glycaemic variability and hyperglycaemia are associated with poor prognosis. GLP‐1 also has a direct action on the myocardium and vasculature—which may be advantageous in the immediate aftermath of a vascular insult. This is a narrative review of the work in this area. The aim was to determine the populations of hospitalised patients being evaluated and the clinical and mechanistic end‐points tested, with the institution of GLP‐1 therapy in hospital. We searched the PubMed, Embase, and Google scholar databases, combining the term “glucagon‐like peptide 1” OR “GLP‐1” OR “incretin” OR “liraglutide” OR “exenatide” OR “lixisenatide” OR “dulaglutide” OR “albiglutide” AND “inpatient” OR “hospital” OR “perioperative” OR “postoperative” OR “surgery” OR “myocardial infarction” OR “stroke” OR “cerebrovascular disease” OR “transient ischaemic attack” OR “ICU” OR “critical care” OR “critical illness” OR “CCU” OR “coronary care unit.” Pilot studies were reported in the fields of acute stroke, cardiac resuscitation, coronary care, and perioperative care that showed advantages for GLP‐1 therapy, with normalisation of glucose, lower glucose variability, and lower risk of hypoglycaemia. Animal and human studies have reported improvements in myocardial performance when given acutely after vascular insult or surgery, but these have yet to be translated into randomised clinical trials." @default.
• W2947155305 created "2019-06-07" @default.
• W2947155305 creator A5010855712 @default.
• W2947155305 creator A5081689241 @default.
• W2947155305 date "2019-06-28" @default.
• W2947155305 modified "2023-09-30" @default.
• W2947155305 title "The use of GLP‐1 receptor agonists in hospitalised patients: An untapped potential" @default.
• W2947155305 cites W1628878549 @default.
• W2947155305 cites W1740216334 @default.
• W2947155305 cites W1903216452 @default.
• W2947155305 cites W1964248774 @default.
• W2947155305 cites W1966056709 @default.
• W2947155305 cites W1968315455 @default.
• W2947155305 cites W1972602694 @default.
• W2947155305 cites W1973832798 @default.
• W2947155305 cites W1975161907 @default.
• W2947155305 cites W1980022623 @default.
• W2947155305 cites W1980717583 @default.
• W2947155305 cites W1982294133 @default.
• W2947155305 cites W1986607710 @default.
• W2947155305 cites W1995209325 @default.
• W2947155305 cites W1998194133 @default.
• W2947155305 cites W2000976083 @default.
• W2947155305 cites W2007994658 @default.
• W2947155305 cites W2010197257 @default.
• W2947155305 cites W2012040949 @default.
• W2947155305 cites W2013665941 @default.
• W2947155305 cites W2019566854 @default.
• W2947155305 cites W2022468655 @default.
• W2947155305 cites W2022485129 @default.
• W2947155305 cites W2027702390 @default.
• W2947155305 cites W2033687786 @default.
• W2947155305 cites W2038523067 @default.
• W2947155305 cites W2042282560 @default.
• W2947155305 cites W2043424819 @default.
• W2947155305 cites W2051298109 @default.
• W2947155305 cites W2051951378 @default.
• W2947155305 cites W2057410639 @default.
• W2947155305 cites W2058202298 @default.
• W2947155305 cites W2062055324 @default.
• W2947155305 cites W2066406526 @default.
• W2947155305 cites W2066634211 @default.
• W2947155305 cites W2072935519 @default.
• W2947155305 cites W2073725657 @default.
• W2947155305 cites W2081250993 @default.
• W2947155305 cites W2082477419 @default.
• W2947155305 cites W2092998122 @default.
• W2947155305 cites W2098393925 @default.
• W2947155305 cites W2102585787 @default.
• W2947155305 cites W2104818363 @default.
• W2947155305 cites W2112592136 @default.
• W2947155305 cites W2112916989 @default.
• W2947155305 cites W2118828771 @default.
• W2947155305 cites W2118877036 @default.
• W2947155305 cites W2120786848 @default.
• W2947155305 cites W2124016563 @default.
• W2947155305 cites W2124719214 @default.
• W2947155305 cites W2129101421 @default.
• W2947155305 cites W2129730863 @default.
• W2947155305 cites W2131556432 @default.
• W2947155305 cites W2139706988 @default.
• W2947155305 cites W2140679565 @default.
• W2947155305 cites W2143018211 @default.
• W2947155305 cites W2144397405 @default.
• W2947155305 cites W2145053281 @default.
• W2947155305 cites W2147537676 @default.
• W2947155305 cites W2148254941 @default.
• W2947155305 cites W2148569002 @default.
• W2947155305 cites W2148706741 @default.
• W2947155305 cites W2148850438 @default.
• W2947155305 cites W2150913805 @default.
• W2947155305 cites W2153814774 @default.
• W2947155305 cites W2154236525 @default.
• W2947155305 cites W2156386917 @default.
• W2947155305 cites W2161564579 @default.
• W2947155305 cites W2162464796 @default.
• W2947155305 cites W2167984392 @default.
• W2947155305 cites W2169976140 @default.
• W2947155305 cites W2176988096 @default.
• W2947155305 cites W2275308782 @default.
• W2947155305 cites W2282578582 @default.
• W2947155305 cites W2313528230 @default.
• W2947155305 cites W2329257022 @default.
• W2947155305 cites W2471875743 @default.
• W2947155305 cites W2509831471 @default.
• W2947155305 cites W2511246393 @default.
• W2947155305 cites W2560522494 @default.
• W2947155305 cites W2597979791 @default.
• W2947155305 cites W2604317643 @default.
• W2947155305 cites W2623846909 @default.
• W2947155305 cites W2624103593 @default.
• W2947155305 cites W2731370549 @default.
• W2947155305 cites W2741125333 @default.
• W2947155305 cites W2749079177 @default.
• W2947155305 cites W2754830681 @default.
• W2947155305 cites W2769260061 @default.
• W2947155305 cites W2773969925 @default.
• W2947155305 cites W2807051677 @default.
• W2947155305 cites W2884417476 @default.
• W2947155305 cites W2895533920 @default.

• next